These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22119591)

  • 21. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.
    Stiegler G; Katinger H
    J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737
    [No Abstract]   [Full Text] [Related]  

  • 22. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
    Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
    AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.
    Veazey RS; Shattock RJ; Pope M; Kirijan JC; Jones J; Hu Q; Ketas T; Marx PA; Klasse PJ; Burton DR; Moore JP
    Nat Med; 2003 Mar; 9(3):343-6. PubMed ID: 12579198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antibody race.
    von Bubnoff A
    IAVI Rep; 2013; 17(1):12-5, 19. PubMed ID: 23678537
    [No Abstract]   [Full Text] [Related]  

  • 28. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Based Preventive and Therapeutic Strategies Against HIV.
    Fabra-Garcia A; Beltran C; Sanchez-Merino V; Yuste E
    Curr HIV Res; 2016; 14(3):260-9. PubMed ID: 26957200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation Mérieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.
    Girard MP; Le-Grand R; Picot V; Longuet C; Nabel GJ
    Vaccine; 2016 Jun; 34(31):3557-61. PubMed ID: 27216761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broadly neutralizing antiviral antibodies.
    Corti D; Lanzavecchia A
    Annu Rev Immunol; 2013; 31():705-42. PubMed ID: 23330954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects for passive immunity to prevent HIV infection.
    Morris L; Mkhize NN
    PLoS Med; 2017 Nov; 14(11):e1002436. PubMed ID: 29136030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
    Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
    Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
    Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
    Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.
    Tudor D; Bomsel M
    AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Not Available].
    Gruell H; Klein F
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():46-9. PubMed ID: 26048121
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 39. HIV: Efficacy through BibNAbs.
    Flemming A
    Nat Rev Drug Discov; 2013 Sep; 12(9):666. PubMed ID: 23989794
    [No Abstract]   [Full Text] [Related]  

  • 40. Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers.
    van den Kerkhof TL; Euler Z; van Gils MJ; Boeser-Nunnink BD; Schuitemaker H; Sanders RW
    AIDS; 2014 May; 28(8):1237-40. PubMed ID: 24556870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.